Andere talen Cidara Therapeutics, Inc.

Aandelen

CDTX

US1717572069

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
11,94 ^USD	+6,70%		+2,75%	-24,81%

15/05	Cidara Therapeutics, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
25/04	Top stijgers premarket	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference	30/05
Cidara Therapeutics: Q1 Earnings Snapshot	15/05
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M	15/05
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	15/05
Cidara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules	15/05
CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX	11/05
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024	26/04
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX	25/04
CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE	25/04
Top Premarket Gainers	25/04
North American Morning Briefing : More Tech -2-	25/04
North American Morning Briefing : More Tech Earnings in Focus With GDP Data Adding to the Uncertainty	25/04
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset	24/04
Cidara Therapeutics, Inc. Announces Board Changes	24/04
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million	24/04
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline	24/04
Mundipharma International Limited acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc..	24/04
Cidara Therapeutics, Inc. announced that it has received $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors	24/04
Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket	23/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cidara Therapeutics, Inc.

Aandelen

CDTX

US1717572069

Andere talen

Filters